Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 514-520

  Mallet, Vincent ^a,b,c   Hamed, Kamal ^d   Schwarzinger, Michaël ^e,f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Translational Health Economics Network   (France)

^f UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Disease progression; End stage liver disease; Epidemiology; Hepatitis B virus; Hepatocellular carcinoma; Prognosis; Risk factors

Indexed keywords

ADULT; ALCOHOLISM; ARTICLE; CHRONIC HEPATITIS B; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DIABETES MELLITUS; DISEASE COURSE; EMERGENCY CARE; END STAGE LIVER DISEASE; FEMALE; FRANCE; HEPATITIS C; HOSPITAL MORTALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SUBACUTE CARE; AGED; COHORT ANALYSIS; COMPLICATION; DISEASE EXACERBATION; EPIDEMIOLOGY; LIVER TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; FRANCE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 85008178611     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.10.031     Document Type: Article

References (29)

1. [1] Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
2. [2] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
3. [3] Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J.F., Bell, B.P., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006), 529–538.
4. [4] Cacciola, I., Pollicino, T., Squadrito, G., Cerenzia, G., Orlando, M.E., Raimondo, G., Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341 (1999), 22–26.
5. [5] Chen, G., Lin, W., Shen, F., Iloeje, U.H., London, W.T., Evans, A.A., Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 101 (2006), 1797–1803.
6. [6] Romeo, R., Del Ninno, E., Rumi, M., Russo, A., Sangiovanni, A., de Franchis, R., et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 136 (2009), 1629–1638.
7. [7] Yang, H.-I., Sherman, M., Su, J., Chen, P.-J., Liaw, Y.-F., Iloeje, U.H., et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 28 (2010), 2437–2444.
8. [8] Yang, H.I., Yuen, M.F., Chan, H.L., Han, K.H., Chen, P.J., Kim, D.Y., et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 12 (2011), 568–574.
9. [9] Yuan, J.M., Govindarajan, S., Arakawa, K., Yu, M.C., Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 101 (2004), 1009–1017.
10. [10] Trinchet, J.C., Bourcier, V., Chaffaut, C., Ait Ahmed, M., Allam, S., Marcellin, P., et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
11. [11] Thio, C.L., Seaberg, E.C., Skolasky, R. Jr., Phair, J., Visscher, B., Munoz, A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 (2002), 1921–1926.
12. [12] Piroth, L., Pol, S., Miailhes, P., Lacombe, K., Lopes, A., Fillion, A., et al. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver Int 35 (2015), 1950–1958.
13. [13] Institut national de la statistique et des études économiques. Répartition des décès selon le lieu du décès [Distribution of deaths according to location]: Institut national de la statistique et des études économiques; 2014 [Available from: http://insee.fr/fr/themes/detail.asp?reg_id=0&ref_id=ir-irsocsd20133 - IRSOCSD20133_SERIE.
14. [14] Hoofnagle, J.H., Reactivation of hepatitis B. Hepatology 49 (2009), S156–S165.
15. [15] Chen, J.-D., Yang, H.-I., Iloeje, U.H., You, S.-L., Lu, S.-N., Wang, L.-Y., et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138 (2010), 1747–1754.
16. [16] Thiebaut, A.C., Benichou, J., Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Stat Med 23 (2004), 3803–3820.
17. [17] Hosmer, D.W., Lemeshow, S., May, S., Regression models for survival data. Applied survival analysis. 2008, John Wiley & Sons, Inc., 67–91.
18. [18] Lin, C.L., Tseng, T.C., Kao, J.H., What can we learn from hepatitis B virus clinical cohorts?. Liver Int 35 (2015), 91–99.
19. [19] Bernier, M.O., Mezzarobba, M., Maupu, E., Caer-Lorho, S., Brisse, H.J., Laurier, D., et al. Role of French hospital claims databases from care units in epidemiological studies: the example of the “Cohorte Enfant Scanner” study. Rev Epidemiol Sante Publique 60 (2012), 363–370.
20. [20] Journy, N., Rehel, J.L., Ducou Le Pointe, H., Lee, C., Brisse, H., Chateil, J.F., et al. Are the studies on cancer risk from CT scans biased by indication? Elements of answer from a large-scale cohort study in France. Br J Cancer 112 (2015), 185–193.
21. [21] Neumann, A., Weill, A., Ricordeau, P., Fagot, J.P., Alla, F., Allemand, H., Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 55 (2012), 1953–1962.
22. [22] Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
23. [23] Tseng, T.-C., Liu, C.-J., Chen, C.-L., Wang, C.-C., Su, T.-H., Kuo, S.F.-T., et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 205 (2012), 54–63.
24. [24] Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155 (2002), 323–331.
25. [25] Fattovich, G., Bortolotti, F., Donato, F., Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008), 335–352.
26. [26] El-Serag, H.B., Hampel, H., Javadi, F., The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4 (2006), 369–380.
27. [27] El-Serag, H.B., Richardson, P.A., Everhart, J.E., The role of diabetes in hepatocellular carcinoma: A case-control study among United States veterans. Am J Gastroenterol 96 (2001), 2462–2467.
28. [28] Papatheodoridis, G., Buti, M., Cornberg, M., Janssen, H., Mutimer, D., Pol, S., et al. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
29. [29] Ryom, L., Boesecke, C., Gisler, V., Manzardo, C., Rockstroh, J.K., Puoti, M., et al. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Med 17 (2016), 83–88.